The blood-brain barrier (BBB) remains a major obstacle to developing effective therapies for neurological and neurodegenerative disease, because most drugs and biologics do not efficiently reach brain tissue.
Old age is attributed to over fifty percent of the global disease burden. While aging is a sign of normal development early in life, it leads to the loss of youthful traits and bodily function in later years.
A team of Stanford researchers have identified a panel of intercellular signaling protein biomarkers that form an aging signature in healthy individuals. One marker, the chemokine CCL11, is specifically correlated with reduced neurogenesis and impaired learning and memory.
Researchers in the Wyss-Coray Lab are investigating a potential therapeutic antibody to treat lysosomal storage disorders and other related neurodegenerative diseases.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
The blood-brain barrier (BBB) lumen is coated by a carbohydrate-rich meshwork known as the brain endothelial glycocalyx layer. Stanford researchers have shown that the brain endothelial glycocalyx is highly dysregulated during aging and neurodegenerative disease.
Researchers in Dr. Anton Wyss-Coray's lab have identified a new therapeutic avenue for treatment of age-related neurodegenerative diseases. Cerebrovascular changes and inflammation are key features of brain aging and neurodegeneration.
Stanford researchers have developed a cell line (MFB-F11) that can be used for an easy, sensitive, and specific bioassay to study the biological functions of Transforming Growth Factor-beta (TGF-beta).